106 related articles for article (PubMed ID: 7616442)
41. Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil.
Cremers B; Flesch M; Südkamp M; Böhm M
J Cardiovasc Pharmacol; 1997 May; 29(5):692-6. PubMed ID: 9213214
[TBL] [Abstract][Full Text] [Related]
42. Effects of Ca2+ channel blockers on Ca2+ loading induced by metabolic inhibition and hyperkalemia in cardiomyocytes.
Tang T; Duffield R; Ho AK
Eur J Pharmacol; 1998 Nov; 360(2-3):205-11. PubMed ID: 9851587
[TBL] [Abstract][Full Text] [Related]
43. The binding interactions of Ro 40-5967 at the L-type Ca2+ channel in cardiac tissue.
Rutledge A; Triggle DJ
Eur J Pharmacol; 1995 Jul; 280(2):155-8. PubMed ID: 7589180
[TBL] [Abstract][Full Text] [Related]
44. Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise.
Muller CA; Opie LH; McCarthy J; Hofmann D; Pineda CA; Peisach M
J Am Coll Cardiol; 1998 Jul; 32(1):268-74. PubMed ID: 9669280
[TBL] [Abstract][Full Text] [Related]
45. Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation.
Billman GE
Eur J Pharmacol; 1992 Dec; 229(2-3):179-87. PubMed ID: 1490522
[TBL] [Abstract][Full Text] [Related]
46. Antioxidant and cytoprotective activities of the calcium channel blocker mibefradil.
Mason RP; Mak IT; Walter MF; Tulenko TN; Mason PE
Biochem Pharmacol; 1998 Jun; 55(11):1843-52. PubMed ID: 9714303
[TBL] [Abstract][Full Text] [Related]
47. Selective inhibition of T-type Ca2+ channels by Ro 40-5967.
Mishra SK; Hermsmeyer K
Circ Res; 1994 Jul; 75(1):144-8. PubMed ID: 8013072
[TBL] [Abstract][Full Text] [Related]
48. Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel.
Schmitt R; Clozel JP; Iberg N; Bühler FR
Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1161-5. PubMed ID: 7627710
[TBL] [Abstract][Full Text] [Related]
49. Mibefradil, A T-type calcium channel antagonist in Y1 cells.
Esneu M; Gallo-Payet N; Payet MD
Endocr Res; 1998; 24(3-4):449-54. PubMed ID: 9888524
[TBL] [Abstract][Full Text] [Related]
50. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil.
Clozel JP; Banken L; Osterrieder W
J Cardiovasc Pharmacol; 1989 Nov; 14(5):713-21. PubMed ID: 2481185
[TBL] [Abstract][Full Text] [Related]
51. Comparative effects of mibefradil and other calcium antagonists on resistance arteries of different end organs.
van der Lee R; Pfaffendorf M; van Zwieten PA
Fundam Clin Pharmacol; 1999; 13(2):198-203. PubMed ID: 10226764
[TBL] [Abstract][Full Text] [Related]
52. Two stable cell lines for screening of calcium channel blockers.
Seisenberger C; Welling A; Schuster A; Hofmann F
Naunyn Schmiedebergs Arch Pharmacol; 1995 Dec; 352(6):662-9. PubMed ID: 9053739
[TBL] [Abstract][Full Text] [Related]
53. Infarct size-limiting properties of Ro 40-5967, a novel nondihydropyridine calcium channel, in anesthetized rats: comparison with verapamil.
Richard V; Tron C; Blanc T; Thuillez C
J Cardiovasc Pharmacol; 1995 Apr; 25(4):552-7. PubMed ID: 7596122
[TBL] [Abstract][Full Text] [Related]
54. Effects of mibefradil on intracellular Ca2+ release in cultured rat cardiac fibroblasts and human platelets.
Eberhard M; Miyagawa K; Hermsmeyer K; Erne P
Naunyn Schmiedebergs Arch Pharmacol; 1995 Dec; 353(1):94-101. PubMed ID: 8750922
[TBL] [Abstract][Full Text] [Related]
55. Novel mode of action of the calcium antagonist mibefradil (Ro 40-5967): potent immunosuppression by inhibition of T-cell infiltration through allogeneic endothelium.
Blaheta RA; Hailer NP; Brude N; Wittig B; Oppermann E; Leckel K; Harder S; Scholz M; Weber S; Encke A; Markus BH
Immunology; 1998 Jun; 94(2):213-20. PubMed ID: 9741343
[TBL] [Abstract][Full Text] [Related]
56. Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family.
Cribbs LL; Lee JH; Yang J; Satin J; Zhang Y; Daud A; Barclay J; Williamson MP; Fox M; Rees M; Perez-Reyes E
Circ Res; 1998 Jul; 83(1):103-9. PubMed ID: 9670923
[TBL] [Abstract][Full Text] [Related]
57. Unique cardioprotective action of the new calcium antagonist mibefradil.
Schulz R; Post H; Jalowy A; Backenköhler U; Dörge H; Vahlhaus C; Heusch G
Circulation; 1999 Jan; 99(2):305-11. PubMed ID: 9892599
[TBL] [Abstract][Full Text] [Related]
58. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers.
Mullins ME; Horowitz BZ; Linden DH; Smith GW; Norton RL; Stump J
JAMA; 1998 Jul; 280(2):157-8. PubMed ID: 9669789
[TBL] [Abstract][Full Text] [Related]
59. The interaction of the calcium antagonist RO 40-5967 with digoxin.
Siepmann M; Kleinbloesem C; Kirch W
Br J Clin Pharmacol; 1995 May; 39(5):491-6. PubMed ID: 7669484
[TBL] [Abstract][Full Text] [Related]
60. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist.
Triggle DJ
Am J Cardiol; 1996 Nov; 78(9A):7-12. PubMed ID: 8903279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
